Company profile
Home - 35 Bio
Applying specialist knowledge to develop small molecule antagonists of genetically-validated GPCR GPR35.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUyNTMzMzE0NWFkaXF6a2N4 | Paper/PDF filed
Published 09 Jun 2026 22:53
MA | Transaction MzUyMDc3MTU5NmFkaXF6a2N4 | Paper/PDF filed
Published 29 May 2026 01:02
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNzAyMjUzM2FkaXF6a2N4
Published 24 Sep 2024 02:34
Company registered at Companies House
1 Jun 2024 to 30 Nov 2025
ThirtyFiveBio has developed a world-leading understanding of how GPR35-signalling promotes gastrointestinal inflammatory metaplasia and cancer disease biology. In recent years, immunotherapy agents, such as checkpoint inhibitors, have led to dramatic survival benefits in some cancer patients. However, the majority of patients still do not respond adequate...
1 Sep 2023 to 31 Aug 2024
ThirtyFiveBio has developed a world-leading understanding of how GPR35-signalling promotes gastrointestinal inflammatory metaplasia and cancer disease biology. In recent years, immunotherapy agents, such as checkpoint inhibitors, have led to dramatic survival benefits in some cancer patients. However, the majority of patients still do not respond adequate...
